Vince Sampson

Cooley advised Nanjing Leads Biolabs Co. (Leads Biolabs), a clinical-stage biotechnology company that discovers, develops and commercializes new therapies in oncology, autoimmune and other severe diseases, on its HK$1.29 billion initial public offering (IPO).

Cooley advised the underwriters of Duality Biologics (DualityBio), a clinical-stage biotech company focused on the discovery and development of next-generation antibody-drug conjugate therapeutics for patients with cancer and autoimmune diseases, in connection with its HK$1.64 billion global initial public offering (IPO).

Cooley advised Structure Therapeutics (Nasdaq: GPCR), a global, clinical-stage biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, on its upsized $547.4 million underwritten public offering.

Cooley advised TriSalus Life Sciences, an oncology company with a focus on treatments for patients with liver and pancreatic tumors, on its merger with MedTech Acquisition Corporation.

Cooley advised Instructure on its $81 million initial public offering. The company now trades on the NYSE under the symbol "INST."

Instructure is an edtech company based in Salt Lake City, Utah. Instructure provides an innovative, cloud-based learning management platform for academic institutions and companies worldwide. Instructure built its learning management applications, Canvas, for the education market, and Bridge, for the corporate market, to enable customers to easily develop, deliver and manage engaging face-to-face and online learning experiences.